Effects of phentermine on striatal dopamine and serotonin release in conscious rats: in vivo microdialysis study. 1998

A Balcioglu, and R J Wurtman
Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences, Cambridge 02139, USA.

OBJECTIVE To measure the effects of phentermine, an appetite supressant, on the release of brain dopamine (DA) and serotonin (5-HT) into striatal dialysates of freely moving rats. METHODS Microdialysis and high performance liquid chromatography. METHODS Unanesthetized rats. METHODS Samples collected every 20 min were assayed for both neurotransmitters in a single run, using high performance liquid chromatography with electrochemical detection. RESULTS Baseline levels of DA and 5-HT in dialysates were 56+/-16 and 3+/-0.6 fmol/20 microl, respectively. Administration of phentermine (2 or 5 mg/kg) increased dialysate DA concentrations to 147+/-17% (P < 0.01) and 320+/-89% (P < 0.01) of baseline, respectively, without significantly affecting 5-HT concentrations. Pretreatment with tetrodotoxin (TTX, 60 min, 1 microM), which abolished the basal release of DA and 5-HT into striatal dialysates, diminished the increase in DA concentrations induced by phentermine, but did not completely block it. Phentermine (2 or 5 mg/kg, i.p.) still stimulated DA release to 27+/-13% and 85+/-15% of baseline, respectively, in the presence of TTX. CONCLUSIONS Phentermine increases brain DA but not 5-HT release in freely moving rats, and TTX reduces, but does not fully block this effect. This pattern is similar to that known to be produced by d-amphetamine.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D008297 Male Males
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D010645 Phentermine A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity. Adipex-P,Duromine,Ionamine,Phentermine Hydrochloride,Adipex P,AdipexP,Hydrochloride, Phentermine
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001067 Appetite Depressants Agents that are used to suppress appetite. Anorectic,Anorectic Agent,Anorectics,Anorexic Drug,Anorexigenic Drug,Appetite Depressant,Appetite Suppressant,Appetite Suppressants,Appetite-Depressing Drug,Appetite-Suppressant Drug,Anorectic Agents,Anorexic Drugs,Anorexigenic Drugs,Appetite-Depressing Drugs,Appetite-Suppressant Drugs,Agent, Anorectic,Agents, Anorectic,Appetite Depressing Drug,Appetite Depressing Drugs,Appetite Suppressant Drug,Appetite Suppressant Drugs,Depressant, Appetite,Depressants, Appetite,Drug, Anorexic,Drug, Anorexigenic,Drug, Appetite-Depressing,Drug, Appetite-Suppressant,Drugs, Anorexic,Drugs, Anorexigenic,Drugs, Appetite-Depressing,Drugs, Appetite-Suppressant,Suppressant, Appetite,Suppressants, Appetite
D012701 Serotonin A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. 5-HT,5-Hydroxytryptamine,3-(2-Aminoethyl)-1H-indol-5-ol,Enteramine,Hippophaine,Hydroxytryptamine,5 Hydroxytryptamine

Related Publications

A Balcioglu, and R J Wurtman
September 1994, The Journal of pharmacology and experimental therapeutics,
A Balcioglu, and R J Wurtman
July 2006, Mechanisms of ageing and development,
A Balcioglu, and R J Wurtman
February 1988, The American journal of physiology,
A Balcioglu, and R J Wurtman
September 1993, British journal of pharmacology,
A Balcioglu, and R J Wurtman
August 1991, Journal of neurochemistry,
Copied contents to your clipboard!